Zion Pharma Announces Global Agreement with Roche to Develop and Commercialize a Blood Brain Barrier Penetrant Oral HER2 Tyrosine Kinase Inhibitor
Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, today announced that Roche has acquired the global rights to Zion’s lead program, ZN-A-1041. ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2). ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer. Up to 50% of patients with HER2-positive metastatic breast cancer will develop brain metastasis during the course of the disease.
"Our agreement with Roche is the culmination of a tremendous team effort to deliver a potentially best-in-class therapy for patients with HER2-positive breast cancer, particularly in the field of brain metastasis by virtue of the high blood-brain barrier permeability of this asset,” stated Zack Cheng, M.D., Ph.D., Chairman, CEO and Co-Founder of Zion Pharma Limited. “Within five years, we have gone from company formation to first-in-human, to finding a partner in Roche, who has the resources and expertise to bring ZN-A-1041 to patients with few other therapeutic options,” Dr. Cheng continued.
Dr. Ding Zhou, Ph.D., CSO and Co-Founder of Zion Pharma Limited added, “We are pleased that Roche recognizes the potential of our asset for advancing the standard of care with regards to brain penetrable compounds in HER2-positive breast cancer.”
“We are excited to enter this partnership with Zion to further develop this innovative treatment option for people with HER2-positive breast cancer. This partnership builds on Roche’s legacy and expertise in the treatment of HER2-positive breast cancer and supports our pursuit of advancing science by combining external innovation with our in-house capabilities to address areas of high unmet patient needs,” said James Sabry, Global Head of Pharma Partnering.
After a transition period, Roche will be responsible for the further development, manufacturing, and commercialization of ZN-A-1041 globally. Zion will receive up to $70 million USD in upfront and near-term milestone payments pending achievement of certain milestone events. Zion will also be eligible for up to $610 million USD in additional payments following achievement of certain development, regulatory, and sales-based milestone events by ZN-A-1041, as well as tiered royalties on sales.
About ZN-A-1041
ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2). ZN-A-1041 was designed to be blood-brain-barrier-penetrant. The ongoing Phase 1 trial is being conducted at multiple sites in the U.S. and China. Additional details will be presented at the poster sessions during the American Society of Clinical Oncology Annual Meeting in June 2023.
About Zion Pharma Limited
Zion Pharma is a private, clinical stage biotech company focused on the development of novel, small molecule, anti-tumoral agents. Founded in 2018, the company’s research headquarters are in Suzhou with additional research operations in Shanghai. The company is applying an innovative drug discovery approach, capitalizing on its DMPK expertise, to develop a pipeline of proprietary first-in-class/best-in-class compounds focused on therapeutic targets which drive tumor inhibition, including ataxia telangiectasia mutated (ATM), Kirsten RAt Sarcoma (KRAS G12D) and SMARCA2 (BRM). Additional information about Zion Pharma is available at www.zionpharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005468/en/
Contact information
For media and partnership inquiries:
J. Michael French
SVP, Corporate Development
michael.french@zionpharma.com
+1.703.338.1972
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetApp named a Leader by Gartner® in the 2025 Magic Quadrant™ for Enterprise Storage Platforms5.9.2025 18:15:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced it has been recognized by Gartner as a Leader in the 2025 Gartner Magic Quadrant for Enterprise Storage Platforms. NetApp believes this recognition reflects how the company’s continuous innovation helps customers build Intelligent Data Infrastructure to face modern technology challenges, including protection from cyber threats and using AI to drive data-based decisions. The evaluation was based on specific criteria that analyzed the company’s overall Completeness of Vision and Ability to Execute. According to Gartner, “Enterprise storage platforms offer platform-native service capabilities and product features for both structured and unstructured data workloads. Heads of infrastructure and operations should use this research to assess vendors in deploying a modern IT infrastructure platform for block, file and object storage.” This report combines the previous Gartner Magic Quadrant reports for the Pri
Capcom’s Popular Title Street Fighter’s Live-Action Movie Starts Filming!5.9.2025 16:00:00 EEST | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that filming has commenced on a live-action film adaptation of its popular fighting game series Street Fighter, in collaboration with Legendary Entertainment (Legendary), with both companies jointly financing the project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250905806122/en/ Street Fighter Movie Title Logo To expand global sales of its core home video game software business, Capcom is actively promoting the branding of its proprietary IP under the Single Content Multiple Usage strategy. Particularly, the adaptation of game content into visual media is a valuable opportunity to broaden awareness of Capcom’s IP beyond the gaming audience. With filming of the upcoming film Street Fighter now starting, the casting of the main characters—Ken, Ryu, and Chun-Li —has been finalized. Through joint financing with Legendary, a company renowned for producing numerous blockbuster fi
Motive’s Entitlement Server Acknowledged as a Pacesetter in Counterpoint Research’s 2025 Rankings5.9.2025 16:00:00 EEST | Press release
Motive, a global leader in device management, today announced its recognition as a Pacesetter in Counterpoint Research’s 2025 Entitlement Server Rankings. Counterpoint placed Motive in its highest top-right Pacesetter quadrant: the most advanced recognition in the ranking. This accolade reflects Motive’s decisive investment in entitlement orchestration at a time when operators face urgent deadlines, including Apple’s September 2025 RCS requirement. Motive has taken the lead, proving ability to deliver at scale, currently deployed in large mobile service providers across North America, Europe, Africa, the Middle East, Asia-Pacific, and Latin America. Removing Barriers to RCS and Beyond The industry has long wrestled with the lack of a commercial framework for Rich Business Messaging (RBM) and lack of cross platform support between Android and iOS. Motive addresses this by ensuring operators can enable RCS on both Apple and Android devices securely without delay. This approach derisks op
Oulu, Finland Prepares for Its European Capital of Culture Year – Explore Upcoming Events5.9.2025 15:31:00 EEST | Press release
“Oulu2026 is created by hundreds of cultural organisations, festivals and creative professionals. The scope is unprecedented, and I believe we will see as many as 3,000 individual events throughout the year,” says Samu Forsblom, Programme Director of Oulu2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250905029974/en/ Spanish flamenco dancer Israel Galván performing at Aalto Silo in 2023, with the Oulu-based screaming men’s choir Huutajat in the background. Photo by Juuso Haarala. From Northern Lights to the Midnight Sun The celebrations begin on 31 December 2025 with a spectacular televised New Year’s Eve show, followed in mid-January by the Oulu2026 Opening Festival, a city-wide weekend of concerts, exhibitions and encounters. Early highlights include international exhibitions – for example, Fotografiska Tallinn and Kiasma presenting their exhibitions in Oulu – the world premiere of a new Sámi opera, and winter gather
RSA Announces CEO Transition to Lead New Phase of Growth5.9.2025 14:00:00 EEST | Press release
RSA, the security-first identity leader, backed by Clearlake Capital Group, L.P. (together with its affiliates) and STG, today announced that Greg Nelson, current President and Chief Business Officer, will succeed Rohit Ghai as Chief Executive Officer on September 15, 2025. Mr. Ghai will transition to a strategic advisory role after serving almost eight years as CEO. Mr. Nelson, a seasoned SaaS executive who has more than 30 years of software, data, technology and private equity experience, is expected to lead RSA into this next phase of accelerated growth. The company’s strategic growth initiatives and investments will focus on: Passwordless – Eliminating reliance on passwords to improve security and user experience Artificial Intelligence (AI) – Leveraging AI to enhance threat detection, prevention, and response Posture Management – Strengthening governance, risk, and compliance capabilities Highest-assurance identity solutions – Protecting the most security-sensitive organizations “
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom